# Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis

> **NCT05119140** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 3 (actual)

## Conditions studied

- Ulcerative Colitis (Disorder)

## Interventions

- **DRUG:** Hydroxychloroquine
- **DRUG:** Mesalamine

## Key facts

- **NCT ID:** NCT05119140
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-10
- **Primary completion:** 2025-05
- **Final completion:** 2025-05
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2025-02-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05119140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05119140, "Administration of Hydroxychloroquine (Plaquenil) to African Americans and Hispanics for the Treatment of Mild to Severe Ulcerative Colitis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05119140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*